It has been more than 4 months since I submitted the manuscript, and there has been no news. Unexpectedly, I was told that no reviewers were found. Is it because of the serious pandemic in Europe and America? SAD!

(41) Thank | Q-q

This is an actual reply: “Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Though this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future.”

(1) Thank | Anonymous

The basic article is being received.

(0) Thank | Adelaide Lawson

Review speed: 3.0 | Submission hit rate: 5.0 Emphasis on research directions: tumors; tumor immunotherapy; solid tumor experience sharing: The impact factor for the year 2023 is 41.6, which is still good overall and still in a leading position in the field of oncology. CA-A CANCER JOURNAL FOR CLINICIANS, 503.1, dominates with one article, without considering Nature Reviews Clinical Oncology 81.3, mainly publishes reviews. ANNALS OF ONCOLOGY, 56.7, mainly reviews. CANCER CELL 48.8, mainly focuses on translational medicine, and starting from the past two years, also publishes some clinical trial articles. JOURNAL OF CLINICAL ONCOLOGY, 42.1, is similar to LANCET ONCOLOGY, ranking equally. Moving down, Cancer Discovery, 29.7, also publishes articles on basic research and translational medicine, which are further from clinical practice. Journal of Hematology & Oncology 29.5 is a comprehensive journal for hematologic tumors and solid tumors. Molecular Cancer 27.7 is also related to tumor translational medicine.

(0) Thank | 是志丹吖

Please translate the following passage into English: 8

(0) Thank | 北国迎荷

Haha, the road of scientific research is long in life

(0) Thank | 混元新曦

The Lancet journal is fine as long as the article is good. If the journal invites submissions, it can still be accepted

(0) Thank | 混元新曦

Impact factor of 51.1, top journal

(0) Thank | 是志丹吖

Submitting articles every day, worrying every day

(0) Thank | 擒龙小谷

It's best

(0) Thank | 坠星倩影

Looking forward, multicenter is the mainstream, everything else is outdated

(0) Thank | 两仪景胜

The editor was very nice, although my submission was ultimately rejected. However, the rejection letter was sincere and included substantive feedback specific to my article. In the end, they recommended another journal and suggested transferring my submission there.

(0) Thank | 一二三四我是小雨点点

Unless it is a super large sample

(0) Thank | 法慧和同

2 weeks to 3 months

(0) Thank | 维尔娜菲茨杰拉德

The review process may be taking longer than expected, and it has not been completed yet

(0) Thank | 维尔娜菲茨杰拉德

Why haven't I heard back after a month of applying?

(0) Thank | 深渊兴业

How long does it usually take for a journal to review a manuscript?

(0) Thank | 北国博达

Of course

(0) Thank | 法慧和同

It is best to add some conversion research

(0) Thank | 法慧和同

Can a purely clinical research RCT be conducted?

(0) Thank | 运骏姑娘

Very visionary

(0) Thank | 采南小姐姐

How many people can share one?

(0) Thank | 深渊妙芙

Are you accepting retrospective cohort studies?

(0) Thank | 太山羽沫

We only accept transformational research articles, not purely foundational ones

(0) Thank | 中原兴思

Zhou often publishes this periodical. 153****5167 (no pseudonym) Published on 2017-02-02 Research area: tumors; cancer; SCI (2015): 26.509 SCI (2014): 24.69 is Zhou Caicun

(0) Thank | 中原兴思